TacticScaleWhat Regeneron Pharmaceuticals Does & How It Makes Money (REGN)
Updated October 2026 · reflects Regeneron Pharmaceuticals's latest reported financials
Biotech company that discovers, makes and sells antibody-based and other medicines. Regeneron earns money by selling its approved injectable medicines and through partnerships, such as its Bayer collaboration on EYLEA, that share development and commercialization of its products.
How Regeneron Pharmaceuticals makes money
Regeneron earns money by selling its approved injectable medicines and through partnerships, such as its Bayer collaboration on EYLEA, that share development and commercialization of its products. It invests those earnings in a large research pipeline and in licensing deals with other biotech companies.
What Regeneron Pharmaceuticals does
Regeneron Pharmaceuticals, founded in 1988 and based in Tarrytown, New York, is a biotechnology company that handles every step from drug discovery through manufacturing and sales. Its marketed medicines include EYLEA and EYLEA 8 mg for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, Dupixent for atopic dermatitis and asthma, Libtayo for advanced cutaneous squamous cell carcinoma, Praluent for familial hypercholesterolemia, and Kevzara for rheumatoid arthritis. It develops and sells EYLEA together with Bayer. Beyond its current products, Regeneron is building out its pipeline through partnerships: RNAi therapeutics with Alnylam, CRISPR gene editing with Intellia, a gene-editing therapy for alpha-1 antitrypsin deficiency with Tessera, a dual GLP-1/GIP receptor candidate (HS-20094) from Hansoh, radiopharmaceuticals with Telix, and conditionally activated bispecific cancer therapies with CytomX. The pipeline covers eye, inflammatory, cardiovascular, metabolic, neurological, infectious and rare diseases, as well as cancer and blood disorders.
Products & services
- EYLEA
- EYLEA 8 mg
- Dupixent
- Libtayo
- Praluent
- Kevzara
What is Regeneron Pharmaceuticals worth?
On an owner-earnings DCF, Regeneron Pharmaceuticals's most-likely value is about $880 versus a recent price near $747 (18% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$427) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
RemeGen (688331.SS) · Amgen (AMGN) · Protagonist Therapeutics (PTGX)